Second Sight Medical Products IncChange company Symbol lookupSelect an option...EYES Second Sight Medical Products IncSJI South Jersey Industries IncDRGV Dragon Capital Group CorpDRCR Dear Cashmere Group Holding CoDMCD Detwiler Fenton Group IncDLDG DLD Group IncCNJG Jufeel International GroupCNGI Concordia Group IncCNCN Chun Can Capital GroupCNBI China BCT Pharmacy Group IncGo
*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
Health Care : Health Care Equipment & Supplies | Small Cap BlendCompany profileSecond Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company intends to develop Orion Visual Cortical Prosthesis which provides useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease or forms of cancer and trauma. Its product, The Argus II Retinal Prosthesis System (The Argus II) provides electrical stimulation of the retina to induce visual perception in blind individuals and helps in treating outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. The Company's Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals.
|
|
|
|
|
Company Profile
Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company intends to develop Orion Visual Cortical Prosthesis which provides useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease or forms of cancer and trauma. Its product, The Argus II Retinal Prosthesis System (The Argus II) provides electrical stimulation of the retina to induce visual perception in blind individuals and helps in treating outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. The Company's Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals.
Valuation Ratios
- Price/Earnings (TTM)
- --
- Price/Sales (TTM)
- 17.94x
- Price/Book (MRQ)
- 5.44x
- Price/Cash Flow (TTM)
- --
MRQ = Most Recent Quarter
Price Performance
Financial Statements
Balance sheet
Values displayed are in thousands.
Income statement
Values displayed are in thousands.
Cash flow
Values displayed are in thousands.
Company Officers
- Gregg G. WilliamsChmn.
- Jonathan McGuirePres.
- John T. BlakeCFO
- Patrick RyanCOO
- William J. Link
Address
- 12744 San Fernando Rd Bldg 3
- Sylmar, CA 91342-3853
- Phone: (818) 833-5000
- Fax: (818) 833-5067
- http://www.secondsight.com/
Insider Trading
During the most recent quarter, 90K shares were bought, and 31K shares were sold in insider trading.
Information provided by , Copyright © 2019. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.